11,319 Shares in Johnson & Johnson (NYSE:JNJ) Bought by WBI Investments Inc.

WBI Investments Inc. purchased a new position in Johnson & Johnson (NYSE:JNJGet Rating) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 11,319 shares of the company’s stock, valued at approximately $1,969,000.

Several other institutional investors have also recently added to or reduced their stakes in the business. Patriot Investment Management Inc. lifted its holdings in Johnson & Johnson by 15.9% in the first quarter. Patriot Investment Management Inc. now owns 21,607 shares of the company’s stock worth $3,829,000 after purchasing an additional 2,964 shares during the period. Choreo LLC raised its holdings in Johnson & Johnson by 1.4% during the 1st quarter. Choreo LLC now owns 10,392 shares of the company’s stock worth $1,842,000 after buying an additional 146 shares during the period. LeJeune Puetz Investment Counsel LLC raised its holdings in Johnson & Johnson by 9.9% during the 1st quarter. LeJeune Puetz Investment Counsel LLC now owns 29,920 shares of the company’s stock worth $5,302,000 after buying an additional 2,705 shares during the period. Montag A & Associates Inc. raised its holdings in Johnson & Johnson by 0.7% during the 1st quarter. Montag A & Associates Inc. now owns 118,889 shares of the company’s stock worth $21,071,000 after buying an additional 829 shares during the period. Finally, Drystone LLC increased its holdings in shares of Johnson & Johnson by 1.3% in the 1st quarter. Drystone LLC now owns 19,414 shares of the company’s stock valued at $3,441,000 after purchasing an additional 251 shares during the period. Institutional investors own 68.78% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on JNJ shares. Citigroup lowered their price target on Johnson & Johnson from $205.00 to $201.00 in a research note on Wednesday, July 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. The Goldman Sachs Group increased their price objective on Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research note on Tuesday, April 12th. Morgan Stanley raised their target price on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research note on Friday, July 8th. Finally, Raymond James raised their price target on Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a report on Wednesday, April 20th. Four equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $189.89.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $174.20 on Friday. The stock has a market cap of $458.39 billion, a P/E ratio of 25.36, a P/E/G ratio of 3.28 and a beta of 0.63. The company has a fifty day moving average price of $176.00 and a two-hundred day moving average price of $174.37. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion for the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a net margin of 19.21% and a return on equity of 36.56%. The company’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the firm earned $2.48 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.05 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd will be given a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a yield of 2.59%. The ex-dividend date is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is 65.79%.

Insider Buying and Selling

In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The shares were sold at an average price of $173.00, for a total transaction of $6,920,000.00. Following the transaction, the executive vice president now directly owns 71,311 shares of the company’s stock, valued at $12,336,803. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now directly owns 15,473 shares in the company, valued at $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by insiders.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).



Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *